132 related articles for article (PubMed ID: 27341410)
21. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
22. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
25. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
26. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
27. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
Schwarz JK; Siegel BA; Dehdashti F; Myerson RJ; Fleshman JW; Grigsby PW
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):180-6. PubMed ID: 17996387
[TBL] [Abstract][Full Text] [Related]
28. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
29. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
31. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
[TBL] [Abstract][Full Text] [Related]
32. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
33. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
34. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma.
Kumar R; Sharma P; Kumari A; Halanaik D; Malhotra A
Clin Nucl Med; 2012 May; 37(5):431-5. PubMed ID: 22475890
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
36. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer.
Zundel MT; Michel MA; Schultz CJ; Maheshwari M; Wong SJ; Campbell BH; Massey BL; Blumin J; Wilson JF; Wang D
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e825-32. PubMed ID: 21300450
[TBL] [Abstract][Full Text] [Related]
37. DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark.
Jakobsen JK; Alslev L; Ipsen P; Costa JC; Krarup KP; Sommer P; Nerstrøm H; Toft BG; Høyer S; Bouchelouche K; Jensen JB
BJU Int; 2016 Jul; 118(1):102-11. PubMed ID: 26216234
[TBL] [Abstract][Full Text] [Related]
38. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
Piperkova E; Raphael B; Altinyay ME; Castellon I; Libes R; Sandella N; Heiba S; Abdel-Dayem H
Clin Nucl Med; 2007 Jun; 32(6):429-34. PubMed ID: 17515747
[TBL] [Abstract][Full Text] [Related]
39. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]